Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





PhI/II Study ofREGN5668 Administered inCombw/Cemiplimab orREGN4018

Cancer
Jill Tseng
Phase I/II Study of REGN5668 (MUC16 × CD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16 × CD3)
Other Female Genital
Ovary

Study Description

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine

the highest, safe dose that can be given to participants with ovarian cancer or cancer of the

uterus

  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

Eligibility

Inclusion

  • Is a woman <18 years of age
  • Is willing and able to comply with clinic visits and study-related procedures and

requirements.

  • Is willing and able to provide informed consent as specified by health authorities and

institutional guidelines.

Exclusion

  • Is currently receiving treatment in another study.
  • Has participated in a study of an investigational agent (except biologics and/or immunotherapy) or an investigational device within 4 weeks of first dose of study drug
  • Prior treatment with a MUC16-targeted therapy.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.